|
|
Second-line chemotherapy with the association
of liposomal daunorubicin, carboplatin and etoposide in children with recurrent
malignant brain tumors
Fiorillo A, Maggi G, Greco N, Migliorati R, D'Amico A, De Caro MD, Sabbatino
MS, Buffardi F
Department of Pediatrics, University Federico II, Naples, Italy.
afiorill@unina.it.
Progressive or recurrent high-grade gliomas are characterized by a very poor
prognosis, and the relevance of second-line chemotherapy is still unassessed.
Although it has been reported that liposomal anthracyclines and carboplatin show
some activity in these patients, their association has never been
investigated.
We have treated six children with recurrent high-grade glioma after surgery,
radiotherapy and chemotherapy, and one child with progressive teratoid/rhabdoid
tumor with the combination of liposomal daunorubicin and carboplatin plus
etoposide.
Five out of seven children showed a major response and the 29 month
progression-free survival was 38%.
The above regimen was feasible and children showed only little and transient
hematological toxicity.
In our opinion, these results justify further investigation of the above
combination chemotherapy for recurrent or progressive malignant brain tumors in
children.
PMID: 15015784 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15015784 |
